Abstract:Recombinant Adeno-associated virus (rAAV) is one of the main delivery vectors for gene therapy. To assess immunogenicity, toxicity, and features of AAV gene therapy in clinical settings, a meta-analysis of 255 clinical trials was performed. A total of 7,289 patients are planned to be dosed. AAV2 was the most dominantly used serotype (29.8%, n=72), and 8.3% (n=20) of trials used engineered capsids. 38.7% (n=91) of trials employed neutralizing antibody assays for patient enrollment, while 15.3% (n=36) used ELISA-based total antibody assays. However, there was high variability in the eligibility criteria with cut-off tiers ranging from 1:1 to 1:1,600. To address potential immunogenicity, 46.3% (n=118) of trials applied immunosuppressants (prophylactic or reactive), while 32.7% (n=18) of CNS and 37.5% (n=24) of ocular-directed trials employed immunosuppressants, possibly due to the immune-privileged status of CNS and retina. There were a total of 11 patient deaths across 8 trials, and 18 out of 30 clinical holds were due to toxicity findings in clinical studies. 30.6% (n=78) of trials had treatment-emergent serious adverse events (TESAEs), with hepatotoxicity and thrombotic microangiopathy (systemic delivery) and neurotoxicity (CNS delivery) being the most prominent. Additionally, the durability of gene therapy may be impacted by two distinct decline mechanisms: 1) rapid decline presumably due to immune responses; or 2) gradual decline due to vector dilution. The durability varied significantly depending on disease indication, dose, serotypes, and patient individuals. Most CNS (90.0%) and muscle trials (73.3%) achieved durable transgene expression, while only 43.6% of ocular trials had sustained clinical outcomes. The rAAV production system can affect rAAV quality and thus immunogenicity and toxicity. Out of 186 trials that have disclosed production system information, 63.0% (n=126) of trials used the transient transfection of the HEK293/HEK293T system, while 18.0% (n=36) applied the baculovirus/Sf9 (rBac/Sf9) system. There were no significant differences in TESAEs and durability between AAV generated by rBac/Sf9 and HEK293/HEK293T systems. In summary, rAAV immunogenicity and toxicity poses significant challenges for clinical development of rAAV gene therapies, and it warrants collaborative efforts to standardize monitoring/measurement methods, design novel strategies to overcome immune responses, and openly share relevant information.

Temporal insights into molecular and cellular responses during rAAV production in HEK293T cells

Production of rAAV by plasmid transfection induces antiviral and inflammatory responses in suspension HEK293 cells

Multi‐omics kinetic analysis of recombinant adeno‐associated virus production by plasmid transfection of HEK293 cells

Proteomic Landscape of Adeno-Associated Virus (AAV)-Producing HEK293 Cells

Comparative transcriptomic and proteomic kinetic analysis of adeno-associated virus production systems

Transcriptomics-informed pharmacology identifies epigenetic and cell cycle regulators as enhancers of AAV production

Proteome profiling and vector yield optimization in a recombinant adeno‐associated virus‐producing yeast model

Enhancement of rAAV titers via inhibition of the interferon signaling cascade in transfected HEK293 suspension cultures

Enhancing the production of recombinant adeno-associated virus in synthetic cell lines through systematic characterization

Comprehensive mRNA‐sequencing‐based characterization of three HEK‐293 cell lines during an rAAV production process for Gene Therapy Applications

Factors affecting rAAV titers during triple-plasmid transient transfection in HEK-293 cells

Enhanced ER protein processing gene expression increases rAAV yield and full capsid ratio in HEK293 cells

High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions

Multidose transient transfection of human embryonic kidney 293 cells modulates recombinant adeno-associated virus2/5 Rep protein expression and influences the enrichment fraction of filled capsids

Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.

Raav Immunogenicity, Toxicity, and Durability in 255 Clinical Trials: A Meta-Analysis

Process Improvement of Adeno-Associated Virus Production

Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production

Unravelling the essential elements for recombinant adeno-associated virus (rAAV) production in animal cell-based platforms

Establishment of an AAV Reverse Infection-Based Array

Advanced biomanufacturing and evaluation of adeno-associated virus